Table 1 Patient and tumor characteristics treated with SOX+B-mab or SOX+C-mab
Characteristics | SOX+B-mab (n = 22) | SOX+C-mab (n = 23) | Total (n = 45) |
|---|---|---|---|
Age, median (range), year | 67 (49–79) | 66 (40–79) | 66 (40–79) |
Sex | |||
 Male | 14 (66.7) | 15 (65.2) | 29 (64.4) |
 Female | 8 (33.3) | 8 (34.8) | 16 (35.6) |
ECOG performance status | |||
 0 | 17 (71.4) | 18 (78.3) | 35 (77.8) |
 1 | 4 (23.8) | 4 (17.4) | 8 (17.8) |
 2 | 1 (4.8) | 1 (4.3) | 2 (4.4) |
TNM at study entry | |||
 T T3 / T4a / T4b | 10 / 11 / 1 | 14 / 4 / 5 | 24 / 15 / 6 |
 N N0 / N1/ N2a / N2b | 5 / 7 / 7 / 3 | 5 / 6 / 9 / 3 | 10 / 13 / 16 / 6 |
 M M1a / M1b / M1c | 12 / 8 / 2 | 8 / 10 / 5 | 20 / 18 / 7 |
Primary tumor resected at study entry | |||
 Yes | 17 (77.3) | 14 (60.9) | 31 (68.9) |
 No | 5 (22.7) | 9 (39.1) | 14 (31.1) |
Metastatic sites at start of treatment | |||
 Liver only | 5 (22.7) | 4 (17.4) | 9 (20.0) |
 Liver | 14 (63.6) | 15 (65.2) | 29 (64.4) |
 Lung | 4 (18.2) | 8 (34.8) | 12 (26.7) |
 Lymph nodes | 15 (68.2) | 15 (65.2) | 30 (66.7) |
 Peritoneum | 3 (13.6) | 5 (21.7) | 8 (17.8) |
 Others | 1 (4.5) | 3 (13.0) | 4 (8.9) |
Colorectal cancer location at diagnosis | |||
 Left | 17 (77.3) | 19 (82.6) | 36 (81.4) |
 Right | 5 (21.7) | 4 (17.4) | 9 (18.6) |